Interview with the Co-Founder, President and CEO: Kura Oncology, Inc. (NASDAQ:KURA)

Healthcare >> CEO Interviews >> May 24, 2016

Troy Wilson is a Co-Founder of Kura Oncology, Inc., and has served as the company’s President and Chief Executive Officer and a member of its board of directors since August 2014. Dr. Wilson, a serial entrepreneur, also has served as President and CEO of Wellspring Biosciences LLC, a private biopharmaceutical company, and its parent company Araxes Pharma LLC since July 2012, and as President and CEO of Avidity NanoMedicines LLC, a private biopharmaceutical company, since November 2012. Before that, Dr. Wilson served as President, CEO and a member of the board of directors of Intellikine Inc., a private biopharmaceutical company, from 2007 until its acquisition by Takeda Pharmaceuticals in 2012. He has been a member of the board of directors of Puma Biotechnology, Inc., since October 2013 and Zosano Pharma, Inc., since June 2014. He also is a member of the board of managers of Araxes Pharma LLC, Avidity NanoMedicines LLC and Wellspring Biosciences LLC. Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley. Profile

TWST: Please tell us about the company's history and focus.

Dr. Wilson: Our entire focus at Kura Oncology, as the name suggests, is to discover and develop

Join for free to read a longer excerpt or purchase this article

Interview with the Co-Founder, President and CEO: Kura Oncology, Inc. (NASDAQ:KURA)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the Co-Founder, President and CEO: Kura Oncology, Inc. (NASDAQ:KURA)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS